
Pharmaids Pharma Sees Revision in Market Evaluation Amidst Challenging Fundamentals
2025-12-04 11:08:19Pharmaids Pharma has undergone a revision in its market evaluation, reflecting a more cautious analytical perspective driven by recent financial and technical developments. The shift highlights concerns over the company’s operational performance and market positioning within the Pharmaceuticals & Biotechnology sector.
Read MoreWhy is Pharmaids Pharma falling/rising?
2025-12-04 00:51:21Recent Price Movement and Market Context Pharmaids Pharmaceuticals Ltd's stock price has demonstrated resilience in the short term, gaining 4.54% over the past week compared to the Sensex's decline of 0.59%. This recent surge contrasts with the stock's longer-term performance, where it has declined by 29.77% year-to-date and 23.85% over the last year, while the Sensex has posted gains of 8.92% and 5.27% respectively over the same periods. Notably, the stock has outperformed its sector by 3.83% on the day of 03-Dec, signalling renewed investor interest. On the day in question, Pharmaids opened with a gap up of 2.54%, indicating strong buying momentum from the outset. The stock reached an intraday high of ₹50.99, marking a 6.94% increase from the previous close, before s...
Read MoreWhy is Pharmaids Pharma falling/rising?
2025-11-17 23:01:35As of 17-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a price increase, currently at Rs 47.82, which reflects a rise of Rs 3.41 or 7.68%. Today's price summary indicates that the stock opened with a gain of 4.48% and reached an intraday high of Rs 48, marking an 8.08% increase. However, despite this positive movement, the stock has shown a decline of 1.24% over the past week and a significant drop of 32.15% year-to-date. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 66.97% against the 5-day average, which may indicate waning interest despite today's gains. Broader market context shows that while Pharmaids Pharmaceuticals has outperformed its sector by 7.4% today, it has underperformed the Sensex over the past week and month, which have seen gains of 1.69% and 1.19%, respectively. The stock's long-term performance remains strong, with a 3-ye...
Read MoreWhy is Pharmaids Pharma falling/rising?
2025-11-14 23:01:57As of 14-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 44.13, which reflects a decrease of Rs 1.68 or 3.67%. The stock has underperformed significantly today, with a performance that is 4.04% lower than its sector. It has also touched an intraday low of Rs 43.9, indicating a drop of 4.17%. The stock is trading below all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), and there has been a notable decrease in investor participation, with delivery volume falling by 29.48% compared to the 5-day average. Furthermore, the stock is close to its 52-week low, being only 4.83% away from Rs 42. The year-to-date return is down by 37.39%, and the one-year return shows a decline of 41.90%, highlighting a significant downturn in performance. In the broader market context, the Sensex has shown a positive return of 1.62% over the past week, contrasting s...
Read MoreHow has been the historical performance of Pharmaids Pharma?
2025-11-12 23:53:35Answer: The historical performance of Pharmaids Pharma shows a gradual increase in net sales, reaching 19.45 Cr in March 2025, up from 15.11 Cr in March 2024 and starting from 0.00 Cr in March 2023. However, the company has consistently reported negative operating profits, with an operating profit of -12.66 Cr in March 2025, slightly worse than -12.33 Cr in March 2024 and -9.88 Cr in March 2023. The total expenditure has risen to 32.21 Cr in March 2025 from 28.32 Cr in March 2024, contributing to a profit before tax of -17.28 Cr in March 2025, compared to -15.62 Cr in March 2024 and -9.91 Cr in March 2023. The profit after tax also reflects this trend, with losses of -13.51 Cr in March 2025, -11.84 Cr in March 2024, and -7.56 Cr in March 2023. The company's total assets increased to 109.35 Cr in March 2025 from 84.67 Cr in March 2024, while total liabilities also rose to 109.35 Cr from 84.67 Cr, indicating ...
Read MoreAre Pharmaids Pharma latest results good or bad?
2025-11-12 19:31:25Pharmaids Pharmaceuticals has reported its financial results for Q2 FY26, revealing a complex situation characterized by significant revenue growth alongside persistent operational challenges. The company achieved net sales of ₹8.61 crores, marking a year-on-year growth of 64.31% and a quarter-on-quarter increase of 29.28%. This represents the highest quarterly revenue in the company's history. However, despite this top-line expansion, Pharmaids continues to face substantial net losses, reporting a consolidated net loss of ₹2.48 crores for the quarter, which reflects a 28.50% deterioration year-on-year. The operating margin remains deeply negative at -61.67%, indicating ongoing struggles with cost management and profitability. The company's PAT margin also stands at a negative -29.38%, underscoring the challenges in converting revenue into profit. Notably, employee costs have risen significantly, consuming...
Read More
Pharmaids Pharmaceuticals Q2 FY26: Mounting Losses and Deteriorating Margins Signal Deepening Crisis
2025-11-12 09:46:45Pharmaids Pharmaceuticals Ltd., a Hyderabad-based micro-cap pharmaceutical company, reported a consolidated net loss of ₹2.48 crores in Q2 FY26, marking a deterioration of 28.50% year-on-year from the ₹1.93 crore loss in Q2 FY25. The company's stock has plummeted 44.43% over the past year, currently trading at ₹46.29 with a market capitalisation of ₹162.00 crores, reflecting investor exodus from this loss-making enterprise.
Read MoreWhen is the next results date for Pharmaids Pharma?
2025-11-07 23:20:02The next results date for Pharmaids Pharma is scheduled for 11 November 2025....
Read MoreWhy is Pharmaids Pharma falling/rising?
2025-11-06 22:50:47As of 06-Nov, Pharmaids Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 46.64, which represents a decrease of Rs 1.57 or 3.26%. The stock has been underperforming, having fallen consecutively for the last two days, resulting in a total drop of 6.38% during this period. Today's trading saw the stock reach an intraday high of Rs 51.91 but ultimately closed at its low. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Despite a rise in delivery volume by 6.9% against the 5-day average, the overall performance today was still below the sector average by 2.49%. In the broader market context, Pharmaids Pharmaceuticals has significantly underperformed compared to the benchmark Sensex over various time frames. For instance, in the past week, the stock has declined by 6.92%, while the Sensex has onl...
Read MoreRe-Lodgement Of Requests For Transfer Of Physical Shares
16-Jan-2026 | Source : BSEReport on shares re-lodged for transfer cum Demat of Physical shares.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
12-Jan-2026 | Source : BSECertificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2025.
Outcome Of The Circular Resolution Dated 05Th January 2026.
05-Jan-2026 | Source : BSEOutcome of the circular resolution dated January 05 2026 for the reconstitution of the Audit and Nomination and Remuneration Committee of the Board.
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available